Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDAPRNewsWire • 12/22/22
Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare ConferencePRNewsWire • 11/22/22
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/22
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business HighlightsPRNewsWire • 11/03/22
Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company MilestonesPRNewsWire • 10/27/22
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/01/22
Akebia Therapeutics Inc. (AKBA) CEO John Butler on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/05/22
Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business HighlightsPRNewsWire • 08/04/22
Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)PRNewsWire • 08/04/22
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with OtsukaPRNewsWire • 06/30/22